key: cord-0914520-3dy3ksfu
authors: Rosell‐Díaz, AM; Mateos‐Mayo, A; Nieto‐Benito, LM; Balaguer‐Franch, I; Hernández de, E; la Torre‐Ruiz,; Laínez‐Nuez, A; Suárez‐Fernández, R; Bergón‐Sendín, M
title: Exanthema and eosinophilia in Covid‐19 patients: has viral infection a role in drug induced exanthemas?
date: 2020-06-04
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16709
sha: 165a44bb182b0ffa0c94c14daa5f6cd6444042d8
doc_id: 914520
cord_uid: 3dy3ksfu

At the present time, the whole world is faced with coronavirus disease 2019 (Covid‐19). Cutaneous manifestations in these patients are being increasingly reported, including rash, acrocyanosis or urticaria(1). Exanthemas in covid‐19 patients are becoming frequent in our daily practice and they pose a challenge regarding their pathogenesis. We present a retrospective case series of twelve adult patients (6 male/6 female) with a mean age of 66,3 years (47‐79). All patients had pneumonia and nasopharyngeal swab PCR positive for SARS CoV‐2 and had received treatment for Covid‐19 per protocol established. Table 1 shows the characteristics of these patients.

discontinued, therefore topical corticosteroids were prescribed. However, the exanthema showed a cephalocaudal progression and confluence with islands of sparing in all cases.

Seven patients developed violaceous-areas and/or target-like ( Fig.1) lesions; of them three developed fever and facial edema. In one patient, the progression of the cutaneous lesions coincided with reintroduction of hydroxychloroquine and lopinavir/ritonavir.

Cutaneous biopsy was performed in two of these patients: one of them showed a superficial perivascular inflammation with eosinophils and the other showed a lichenoid pattern with eosinophils. Both two were compatible with drug reaction.

Systemic corticosteroids were prescribed in six patients with violaceous areas, starting at 0,5-1mg/kg and then tapered over the ensuing 2-4 weeks with progressive improvement.

The other cases improved with topical corticosteroids.

It has been suggested that underlying viral infections may increase the risk of adverse drug reactions. The association of viral infections and drug reactions has been described in many clinical situations, such as the ampicillin rash in infectious mononucleosis or the increased risk of drug reactions in AIDS patients (2) . In DRESS syndrome, viral reactivation (especially HHV-6) is a characteristic feature. Antiviral immune responses may facilitate drug allergy development and several biological mechanisms have been proposed for this effect, including excessive production of proinflammatory cytokines, which has been observed in Covid-19 (3) , (4) .

The presence of exanthema and eosinophilia suggests a drug reaction in our patients.

DRESS syndrome, although unusual, has been reported related to hydroxychloroquine but it has not been described with lopinavir/ritonavir (5) . Other drug reactions have also been reported with the treatments used for Covid-19 management. However, the high frequency we are observing these reactions in the Covid-19 pandemic, make us think that SARS-CoV-2 infection may have a role in their pathogenesis. We suggest that several exanthemas may result from interaction between antiviral immune response and drugs. Nevertheless, more studies are needed to confirm this hypothesis. We must be cautious until then. It would be therefore strongly recommended that all Covid-19 patients with exanthema and eosinophilia were investigated for drug sensitization.

We suggest that systemic corticosteroids should be considered in those exanthemas that progress to violaceous areas or target-like lesions, since in our experience topical corticosteroids have not been able to achieve an improvement in these cases. 

This article is protected by copyright. All rights reserved 

Cutaneous manifestations in COVID-19: a first perspective

A complex interaction between drug allergy and viral infection

Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses

COVID-19: consider cytokine storm syndromes and immunosuppression

A case of an acute cutaneous drug reaction with hydroxychloroquine

Accepted Article

The patients in this manuscript have given written informed consent to publication of their case details.

This article is protected by copyright. All rights reserved